Six drugs have been launched for the treatment of castration-resistant prostate cancer since 2010, i.e., CYP17 inhibitor Abiraterone, AR antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, RANKL antibody Denosumab and radiopharmaceutical Alpharadin. The gene discussed is AR; the disease is Familial prostate cancer.